文献速递炎症性肠病

轻度炎症性肠病的患病率与预后:1997-2020年基于人群的队列研究

Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997-2020.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-13

在丹麦北区1997-2020年4607例IBD患者中,初始轻度IBD共2315例,随访期间24.5%的UC(n=474)和46%的CD(n=174)进展为中重度疾病;诊断时年龄<18岁者进展可能性最高,轻度病程延长则进展概率降低。

要点

  • 初始轻度UC患者中24.5%(n=474)进展为中重度疾病。
  • 初始轻度CD患者中46%(n=174)进展为中重度疾病。
  • 诊断时年龄<18岁者进展可能性最高,轻度病程延长则进展概率降低。

核心结论

  • 诊断后1年内属轻度UC者约四分之一、轻度CD者约二分之一随时间进展为中重度疾病。
  • 诊断时年轻增加进展概率,而轻度病程延长则降低进展概率。

研究设计与样本

  • 基于人群的队列研究,纳入丹麦北区1997至2020年诊断的所有IBD患者(n=4607)。
  • 依据诊断后第一年内治疗史定义轻度疾病,随访其进展为中重度疾病。

主要发现

  • 2315例初始轻度IBD中,24.5%的UC(n=474)和46%的CD(n=174)在随访期间进展为中重度疾病。
  • 全部IBD人群中,52.3%的UC患者和86.8%的CD患者在随访期间进展。
  • 轻度UC进展为中重度UC的10年概率:轻度病程1年后为26%,5年后为19%,10年后为12%。
  • 轻度CD进展为中重度CD的概率:轻度病程1年后为53%,5年后为34%,10年后为33%。
  • 诊断时年龄<18岁者进展可能性最高。

关键数值与推荐

  • 中重度疾病采用复合结局定义:免疫调节剂、生物制剂治疗、IBD相关住院和/或手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD), are heterogenous diseases ranging from mild to severe. We aimed to describe the prevalence and prognosis of mild IBD in an unselected population-based patient cohort. METHODS: We identified all individuals diagnosed with IBD during 1997 to 2020 in North Denmark (n = 4607). Patients with mild disease, based on treatment history within the first year, were followed for progression to moderate-severe disease, based on a composite outcome of immunomodulators, biologic therapies, IBD-related hospitalization, and/or surgery. We used time-to-event analysis to calculate probabilities of progression based on IBD subtype, age, sex, and duration of mild IBD. RESULTS: Among 2315 individuals with initial mild IBD, 24.5% with UC (n = 474) and 46% with CD (n = 174) progressed to moderate-severe disease during follow-up. Of the total IBD population, 52.3% of patients with UC and 86.8% with CD progressed during follow-up. Individuals <18 years at diagnosis were the most likely to progress. The 10-year probability of progressing to moderate-severe UC was 26% after 1 year with mild disease, 19% after 5 years, and 12% after 10 years. The probability of progressing to moderate-severe CD was 53% after 1 year with mild disease, 34% after 5 years, and 33% after 10 years. CONCLUSIONS: Approximately one-fourth of individuals with mild UC within 1 year after diagnosis and one-half of those with mild CD progressed to moderate-severe disease over time. Young age at diagnosis increased the probability of progression, whereas increasing duration of mild disease decreased the probability.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jacobsen HA, Karachalia-Sandri A, Ebert AC, et al. Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997-2020. Clin Gastroenterol Hepatol. 2024. PMID: 39675406. doi:10.1016/j.cgh.2024.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。